$ATNF So If I understand the Dupuytren’s disease treatment and Frozen shoulder correctly we are basically copying a well known extremely expensive proven blockbuster drug (Humera)adalimumab and going to alter it slightly and then sell it for frozen shoulder and Dupurytrens disease. So if someone can correct me since this is just a bio-similar drug if 180 life science can sell it cheaper than Humera can doctors just prescribe off label use of our new drug and make money off other diseases as doctors prescribe it for off label instead. Looks like this biosimilar drug is going to get approved. Are other biosimilar Humera drugs going to be able to treat Dupuytren’s diesease or do they have to go to clinical trials?